|
|
|
|
|
Press Release - Regulated Information |
|
|
|
Additional information: |
This transparency notification covers the following transactions:
|
(i) |
sale of 6,500,000 shares of Celyad Oncology from CFIP CLYD LLC to CFIP CLYD (UK) Limited on 30 August 2023
within the scope of an intragroup share transfer; and |
|
(ii) |
subscription to 1,454,808 newly issued shares of Celyad Oncology by CFIP CLYD (UK) Limited on 4 September
2023. |
After both transactions, CFIP CLYD (UK) Limited will hold 7,954,808 shares of Celyad Oncology.
Miscellaneous
|
|
|
The Press Release may be consulted on the website of Celyad Oncology: |
https://celyad.com/newsroom/
|
|
|
The notification can be consulted on the website of Celyad Oncology: |
https://celyad.com/investors/regulated-information/
Any transparency notification must be sent to our Company by email to the attention of Georges Rawadi, Chief Executive Officer (CEO):
investors@celyad.com
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric
antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation
CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell
therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.
Forward-looking statements
This release may contain
forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs about and expectations for the
Companys updated strategic business model, including associated potential benefits, transactions and partnerships, statements regarding the potential value of the Companys IP, and statements regarding the transparency notification. The
words will, believe, potential, continue, target, project, should and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any forward-looking statements in this release are based on managements current expectations and beliefs and are subject to a number of known and unknown risks, uncertainties and
important factors which might cause actual events, results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties
include, without limitation, risks related to the material uncertainty about the Companys ability to continue as a going concern; the Companys ability to realize the expected benefits of its updated strategic business model; the
Companys ability to develop its IP assets and enter into partnerships with outside parties; the Companys ability to enforce its patents and other IP rights; the possibility that the Company may infringe on the patents or IP rights of
others and be required to defend against patent or other IP rights suits; the possibility that the Company may not successfully defend itself against claims of patent infringement or other IP rights suits, which could result in substantial claims
for damages against the Company; the possibility that the Company may become involved in lawsuits to protect or enforce its patents, which could be expensive, time-consuming, and unsuccessful; the Companys ability to protect its IP rights
throughout the world; the potential for patents held by the Company to be found invalid or unenforceable; and other risks identified in Celyad Oncologys U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest
Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document
Page 3 of 3